Clinical Trials
61 trialsNCT06708936 2026-05-08
KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study
Kousai Bio Co., Ltd.
Phase EARLY_PHASE1 Withdrawn
NCT07284953 2026-03-13
PuraBond
The Royal Wolverhampton Hospitals NHS Trust
Phase NA Withdrawn
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT06603155 2025-12-19
Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC)
Duke University
Phase NA Withdrawn
NCT07084909 2025-12-10
HARRIER
Lantheus Medical Imaging
Phase 2/3 Withdrawn
NCT06361810 2025-08-19
PSMA Therapy and Immunotherapy in Kidney Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Withdrawn
NCT07011849 2025-08-13
Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02671552 2025-05-02
Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery
Thomas Jefferson University
Phase EARLY_PHASE1 Withdrawn
NCT05418387 2024-11-25
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
University of Arizona
Phase NA Withdrawn
NCT04580836 2024-10-26
MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02232646 2023-11-14
A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies
Sumitomo Pharma America, Inc.
Phase 2 Withdrawn
NCT06090318 2023-10-19
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Rain Oncology Inc
Phase 1/2 Withdrawn
NCT00489710 2023-08-22
Talabostat in Treating Patients With Metastatic Kidney Cancer
University of Nebraska
Phase 2 Withdrawn
NCT00499291 2023-05-25
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
Eastern Cooperative Oncology Group
Phase NA Withdrawn
NCT04603365 2023-05-17
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01769885 2022-08-15
Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer
Roswell Park Cancer Institute
Phase NA Withdrawn
NCT05263609 2022-08-02
Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
University of Oklahoma
Phase 2 Withdrawn
NCT04961320 2022-06-09
Occupational Therapy Fatigue Management-Based Intervention for Metastatic Renal Cell Carcinoma
City of Hope Medical Center
Phase NA Withdrawn
NCT05104905 2022-05-11
RENACOL
Faron Pharmaceuticals Ltd
Phase 1/2 Withdrawn
NCT02061605 2022-04-06
LTW-KIDNEY
Laser Tissue Welding, Inc.
Phase NA Withdrawn
NCT03035630 2022-02-15
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT04648826 2021-12-17
Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT03189186 2021-04-05
Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas
University of California, Irvine
Phase 1 Withdrawn
NCT04262375 2020-11-17
DOMINATION
University Health Network, Toronto
Phase 2 Withdrawn
NCT03598816 2020-08-13
PIVOT-RCC
Washington University School of Medicine
Phase 2 Withdrawn
NCT04260360 2020-08-04
Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
NanOlogy, LLC
Phase 1 Withdrawn
NCT03927248 2020-05-07
PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
HealthPartners Institute
Phase 1/2 Withdrawn
NCT03943771 2020-01-27
R3DP-A
University Hospital, Bordeaux
Phase NA Withdrawn
NCT03408561 2019-09-17
Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer
University of Southern California
Phase NA Withdrawn
NCT03111901 2019-07-12
UVA-AM-002
University of Virginia
Phase 1/2 Withdrawn
NCT03528057 2019-07-05
Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial Nephrectomy
Northwestern University
Phase NA Withdrawn
NCT02867332 2019-03-06
PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.
Peking University
Phase 1 Withdrawn
NCT03323710 2019-01-09
Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma
Military Institute od Medicine National Research Institute
Phase 2 Withdrawn
NCT03693573 2018-11-15
A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
Hoffmann-La Roche
Phase 3 Withdrawn
NCT03226236 2018-11-13
RENALVax-2
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 2 Withdrawn
NCT02763761 2018-10-09
An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo
Bristol-Myers Squibb
Phase 2 Withdrawn
NCT03149159 2018-06-18
Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab
Medical University of South Carolina
Phase 2 Withdrawn
NCT02962804 2018-03-05
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
University of Kansas Medical Center
Phase 2 Withdrawn
NCT01762592 2017-12-22
REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT
Heidelberg Pharma AG
Phase 3 Withdrawn
NCT02370342 2017-12-20
Robot-Assisted Ultrasound for Thermal Ablative Therapy in Treating Patients With Small Kidney Masses Undergoing Surgery
University of Southern California
Phase NA Withdrawn
NCT00769990 2017-12-13
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
Masonic Cancer Center, University of Minnesota
Phase 1/2 Withdrawn
NCT01176500 2017-07-02
A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Withdrawn
NCT00061178 2016-10-19
Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma
Genentech, Inc.
Phase 3 Withdrawn
NCT00556205 2016-03-24
Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma
Massachusetts General Hospital
Phase 2 Withdrawn
NCT02307474 2016-03-03
A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer
Case Comprehensive Cancer Center
Phase NA Withdrawn
NCT01977586 2015-11-23
Functional Imaging in the Assessment of mRCC Response to Sunitinib
Imperial College Healthcare NHS Trust
Phase NA Withdrawn
NCT00006126 2015-11-13
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
Northwestern University
Phase 1 Withdrawn
NCT01104389 2015-08-26
Fluorescence Imaging on the da Vinci Surgical System for Intraoperative Near Infrared Imaging
Intuitive Surgical
Phase NA Withdrawn
NCT00574483 2015-08-03
Treatment of Advanced Renal Cell Carcinoma With Quinacrine
Cleveland BioLabs
Phase 2 Withdrawn
NCT00176280 2015-06-18
Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma
University of Kentucky
Phase 2 Withdrawn